Striking gold: Finding ultra-rare variants in liquid biopsy samples using targeted NGS
Why is rare variant detection and discovery from cfDNA so challenging?
Studies have shown that both cfDNA and ctDNA correlate with disease progression and reoccurrence and assist in therapy guidance. But cfDNA is highly fragmented, unstable in biofluids and at low concentrations in non-advanced, non-metastatic cancers. Meanwhile, ctDNA represents just 1–2% of total cfDNA. Add in sequencing reaction errors, enrichment biases and false positives, and you will need a lower limit of detection (LOD) of about 0.1% variant allele frequency (VAF) to find those valuable insights. To be confident in your rare variant identification, cfDNA requires highly sensitive and specific techniques.
Join us for a webinar discussing the newest technology for reliable detection of ultra-rare variants at a 0.1% VAF from cfDNA and go from sample to sequencing-ready library in just 8 hours. We will discuss the following:
- The biggest challenges in liquid biopsy variant detection
- Our new QIAseq chemistry and workflow
- Simplified data analysis with our integrated bioinformatics pipeline
Explore how our new QIAseq Targeted cfDNA Ultra Panels can help you unlock the potential in your liquid biopsy samples.